#	Pagina
attuale pagina	/open-h2020/projects/204397/index.html

Opendata, web and dolomites

OPTIMIsE

Commercial feasibility of the Novio-PlainGel: a novel synthetic, reversible thermosensitive, biomimetic hydrogel for organoid-based precision medicine

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

OPTIMIsE project word cloud

Explore the words cloud of the OPTIMIsE project. It provides you a very rough idea of what is the project "OPTIMIsE" about.

noviocell batch sarcoma clinical proprietary company spur variability later reversible tissue unmet hydrogel drug biotechnology material ex cell mini innovative organoids immunologic extract market possibilities builds platform commercial downstream pic precision clinics thermosensitive stem million feasibility bv initially mouse optimise bio transmission excellent exponentially combination personalised profitability ease thermo organoid recovery basement matrix small proof cumulative medicine perform diagnostic biomechanics performance risk natural optimal hydrogels models culturing polyisocyanopeptide culture sensitive matrices vivo standard disease revenues stage gt organs 3d uniquely pancreatic cancer validation biomaterial sub cultured extracellular membrane introduction pathogen hampered up synthetic matrigel

Project "OPTIMIsE" data sheet

The following table provides information about the project.

Coordinator	NOVIOCELL BV Organization address address: KLOOSTERSTRAAT 9 RE1131 city: OSS postcode: 5349 AB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.noviocell.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2016-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	NOVIOCELL BV NOVIOCELL BV Organization address address: KLOOSTERSTRAAT 9 RE1131 city: OSS postcode: 5349 AB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (OSS)	coordinator	50˙000.00

Map

Project objective

Noviocell BV is a highly innovative biotechnology company and builds upon its proprietary polyisocyanopeptide (PIC) hydrogel. This is a novel synthetic, reversible thermosensitive hydrogel for 3D cell culturing. PIC hydrogels uniquely perform like a natural biomaterial, while being fully reversible thermo-sensitive, which allows for ease of cell/tissue recovery and easy downstream processing after culturing. In addition, PIC hydrogel has a unique combination of bio-functionality and biomechanics that makes them excellent matrices for 3D stem cell culture. During OPTIMIsE, Noviocell BV will investigate the technical and commercial feasibility of using the PIC hydrogel as a platform for the clinical use of organoids (mini organs ex vivo). The use of organoids in a clinical set-up has the potential to open up unique possibilities for precision medicine, as it can facilitate organoid-based drug testing and provide disease specific models. However, their clinical use is currently hampered because of batch-to-batch variability, sub-optimal extracellular matrix, small scale production and the risk of immunologic response and pathogen transmission (as they cultured in Matrigel which a basement membrane extract from mouse sarcoma). The PIC hydrogel, due to its unique characteristic, can address these unmet needs and facilitate the use of organoids for personalised medicine. The validation of PIC hydrogel initially as the best hydrogel for growing organoids (using pancreatic organoids as a proof of concept) and at a later stage as a diagnostic platform in clinics will spur the profitability and growth performance of Noviocell BV. It is estimated that within 5 years after market introduction of the PIC hydrogel, Noviocell BV will have cumulative revenues of >€40,7 million (only in the pancreatic cancer market). These revenues will exponentially increase when the PIC hydrogel will become the standard material for growing organoids.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTIMISE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTIMISE" are provided by the European Opendata Portal: CORDIS opendata.